Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach
AbstractThe conventional method of one drug being used for one target has not yielded therapeutic solutions for Lewy body dementia (LBD), which is a leading progressive neurological disorder characterized by significant loss of neurons. The age-related disease is marked by memory loss, hallucinations, sleep disorder, mental health deterioration, palsy, and cognitive impairment, all of which have no known effective cure. The present study deploys a network medicine pipeline to repurpose drugs having considerable effect on the genes and proteins related to the diseases of interest. We utilized the novel SAveRUNNER algorithm ...
Source: Journal of Molecular Neuroscience - February 16, 2024 Category: Neuroscience Source Type: research
Benefit and risk evaluation of quinapril hydrochloride
Expert Opin Drug Saf. 2023 Apr 17:1-7. doi: 10.1080/14740338.2023.2203481. Online ahead of print.ABSTRACTINTRODUCTION: Angiotensin-converting enzyme (ACE) inhibitors are a mainstay of antihypertensive therapy. Quinapril hydrochloride, a less commonly used, and less-studied ACE inhibitor has been approved for its primary use in hypertension. Studies also indicate its off-label use for congestive heart failure and diabetic nephropathy. The ANDI and TREND trials have been pivotal in demonstrating the effectiveness of quinapril.AREAS COVERED: The authors conducted a review of the literature analyzing the clinical efficacy and ...
Source: Expert Opinion on Drug Safety - April 15, 2023 Category: Drugs & Pharmacology Authors: Maryam Barkhordarian Jannel A Lawrence Sebahat Ulusan Muhammed Ibrahim Erbay Wilbert S Aronow Rahul Gupta Source Type: research
Benefit and risk evaluation of quinapril hydrochloride
Expert Opin Drug Saf. 2023 Apr 15. doi: 10.1080/14740338.2023.2203481. Online ahead of print.ABSTRACTINTRODUCTION: Angiotensin-converting enzyme (ACE) inhibitors are a mainstay of antihypertensive therapy. Quinapril hydrochloride, a less commonly used, and less-studied ACE inhibitor has been approved for its primary use in hypertension. Studies also indicate its off-label use for congestive heart failure and diabetic nephropathy. The ANDI and TREND trials have been pivotal in demonstrating the effectiveness of quinapril.AREAS COVERED: The authors conducted a review of the literature analyzing the clinical efficacy and safe...
Source: Expert Opinion on Drug Safety - April 15, 2023 Category: Drugs & Pharmacology Authors: Maryam Barkhordarian Jannel A Lawrence Sebahat Ulusan Muhammed Ibrahim Erbay Wilbert S Aronow Rahul Gupta Source Type: research
Interventions to Decrease Carotid-Intima Media Thickness in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis
CONCLUSIONS: Some pharmacological interventions may decrease CIMT in children with type 1 diabetes. However, there is great uncertainty with respect to their effects and no strong conclusions can be drawn. Further evidence from larger RCTs is required.SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42017075169.PMID:36992735 | PMC:PMC10012108 | DOI:10.3389/fcdhc.2022.882504 (Source: Atherosclerosis)
Source: Atherosclerosis - March 30, 2023 Category: Cardiology Authors: Adina Mihaela Epure Daniela Anker Stefano Di Bernardo Bruno R da Costa Nicole Sekarski Arnaud Chiolero Source Type: research
Binder jetting 3D printing of challenging medicines: from low dose tablets to hydrophobic molecules
Eur J Pharm Biopharm. 2021 Nov 13:S0939-6411(21)00274-5. doi: 10.1016/j.ejpb.2021.11.001. Online ahead of print.ABSTRACTIncreasing access to additive manufacturing technologies utilising easily available desktop devices opened novel ways for formulation of personalized medicines. It is, however, challenging to propose a flexible and robust formulation platform which can be used for fabrication of tailored solid dosage forms composed of APIs with different properties (e.g., hydrophobicity) without extensive optimization. This manuscript presents a strategy for formulation of fast dissolving tablets using binder jetting (BJ)...
Source: European Journal of Pharmaceutics and Biopharmaceutics - November 17, 2021 Category: Drugs & Pharmacology Authors: Marta Kozakiewicz Karol P Nartowski Aleksandra Dominik Katarzyna Malec Anna M Go łkowska Adrianna Z łocińska Ma łgorzata Rusińska Patrycja Szymczyk-Zi ółkowska Grzegorz Zi ółkowski Agata G órniak Bo żena Karolewicz Source Type: research
Binder jetting 3D printing of challenging medicines: from low dose tablets to hydrophobic molecules
Eur J Pharm Biopharm. 2021 Nov 13:S0939-6411(21)00274-5. doi: 10.1016/j.ejpb.2021.11.001. Online ahead of print.ABSTRACTIncreasing access to additive manufacturing technologies utilising easily available desktop devices opened novel ways for formulation of personalized medicines. It is, however, challenging to propose a flexible and robust formulation platform which can be used for fabrication of tailored solid dosage forms composed of APIs with different properties (e.g., hydrophobicity) without extensive optimization. This manuscript presents a strategy for formulation of fast dissolving tablets using binder jetting (BJ)...
Source: European Journal of Pharmaceutics and Biopharmaceutics - November 17, 2021 Category: Drugs & Pharmacology Authors: Marta Kozakiewicz Karol P Nartowski Aleksandra Dominik Katarzyna Malec Anna M Go łkowska Adrianna Z łocińska Ma łgorzata Rusińska Patrycja Szymczyk-Zi ółkowska Grzegorz Zi ółkowski Agata G órniak Bo żena Karolewicz Source Type: research
Angiotensin-converting enzyme inhibitors induced angioedema: not always a class effect? A case report and short narrative review
We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Angioedema subsided spontaneously after ramipril discontinuation and quinapril reintroduction.Discussion and conclusions: Our clinical case suggests that despite similar pharmacodynamic properties, quinapril and ramipril do not have the same potential to generate angioedema. To explain this difference, we suggest a potentiation of the effect of bradykinin at the B2 receptor level by ramipril, which does not occur with quinapril. Consequently, angioedema could not always be a class effect of ACE inhibitor...
Source: Current Medical Research and Opinion - August 20, 2021 Category: Research Authors: Guillaume Becker Fabien Rougerie Amelia-Naomi Sabo Marie-Caroline Dalmas Estelle Ayme-Dietrich Laurent Monassier Source Type: research
Drugs for Chronic Heart Failure
Date: June 14, 2021
Issue #:
1626Summary:
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF)≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF. (Source: The Medical Letter)
Source: The Medical Letter - April 21, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Accupril ACE inhibitors Aldactone Altace ARBs Atacand Beta blockers BiDil Bisoprolol Bumetanide Burinex Candesartan Captopril Carvedilol cilazapril Coreg Corlanor Coversyl Cozaar dapagliflozin Digoxin Diovan Diu Source Type: research
iTRAQ-based proteomics and in vitro experiments reveals essential roles of ACE and AP-N in the renin-angiotensin system-mediated congenital ureteropelvic junction obstruction.
CONCLUSION: Suppression of ACE and AP-N expression mediates congenital UPJO pathogenesis by repressing renal tubular epithelial proliferation, promoting ROS production, and enhancing inflammatory factor expression.
PMID: 32416091 [PubMed - as supplied by publisher] (Source: Experimental Cell Research)
Source: Experimental Cell Research - May 12, 2020 Category: Cytology Authors: Liu R, Zhang W, Luo M, Qin X, Yang F, Wei Q Tags: Exp Cell Res Source Type: research
Drugs for Hypertension
Date: May 18, 2020
Issue #:
1598Summary:
Drugs available for treatment of chronic hypertension
and their dosages, adverse effects, and costs are
listed in the tables. Treatment
of hypertensive urgencies and emergencies is not
discussed here. (Source: The Medical Letter)
Source: The Medical Letter - April 29, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Accupril Accuretic ACE inhibitors Acebutolol Adalat Aldactone aliskiren Altace Amiloride Amlodipine ARBs Atacand Atenolol Avalide Avapro azilsartan benazapril Benicar Beta blockers Betaxolol Bisoprolol Bumetanide Source Type: research
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults
AbstractPurpose of ReviewSystematic review of angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARB) in the prophylactic treatment of adults with migraine. To identify gaps in research and provide guidance for future clinical trials.Recent FindingsA search was completed using PubMed, MEDLINE, Embase, and the Cochrane Library January 1, 1990 through December 31, 2017. The following are keywords used in the search: migraine, migraine prophylaxis/prevention, renin-angiotensin-aldosterone system, RAAS, ACE inhibitors, angiotensin-converting enzyme inhibitors: quinapril, perindopril, r...
Source: Current Pain and Headache Reports - September 11, 2019 Category: Neurology Source Type: research
Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine
Publication date: Available online 6 April 2019Source: Chemico-Biological InteractionsAuthor(s): Noriaki Ikemura, Satoshi Yamaori, Chinatsu Kobayashi, Shinobu Kamijo, Norie Murayama, Hiroshi Yamazaki, Shigeru OhmoriAbstractThe inhibitory effects of antihypertensive drugs (dihydropyridine calcium channel blockers, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors) on cytochrome P450 2J2 (CYP2J2) activity were examined. Amlodipine, azelnidipine, barnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, nilvadipine, nisoldipine, nitrendipine, telmisartan, ...
Source: Chemico Biological Interactions - April 8, 2019 Category: Biochemistry Source Type: research
